|
FDA: Asthma Drug May Increase Risk of CV, Cerebrovascular Events
Monthly Prescribing Reference The Food and Drug Administration (FDA) is warning about a slightly increased risk of cardiovascular and cerebrovascular events among patients being treated with Xolair (omalizumab; Genentech and Novartis) for asthma compared to those not treated with … Xolair (omalizumab): Drug Safety Communication – Slightly Elevated Risk of … |
View full post on asthma – Google News